Arthritis Australia’s commitment to helping you through the COVID-19 Pandemic

From our CEO:
Dear friends,
The COVID-19 pandemic is impacting many aspects of our life and work which may have a profound impact for years to come. Our thoughts and prayers are with those who are affected at home in Australia, and worldwide. 
Today, we are pleased to bring you this ‘Special Edition’ of the Arthritis Australia e-Newsletter. This is in response to the unprecedented circumstances facing people who are living with arthritis, and in particular, those Australians taking immunosuppressant medications. We draw your attention to newly added ‘COVID-19’ section on the Arthritis Australia website which brings together the latest news and research updates available. We hope that you find this information valuable.
We are, as always, keen to hear of your experiences, so please let us know if we, or the wonderful staff at the arthritis Affiliate offices, can help you.
Very best regards – Andrew Mills
CEO, Arthritis Australia
Information for consumers
Our community can be assured that Arthritis Australia will continue to provide the most up to date and reliable information regarding COVID-19 and arthritis. Our Consumer information regarding Coronavirus (COVID-19) page, located on the Arthritis Australia website, is being updated regularly and as new information is being released. Here you will find information on how to protect yourself & others, who is most at risk, advice about medicines, COVID-19 specific programs and resources, and other important information.
Australian Rheumatology Association updated statement
The ARA has updated their statement, and stresses that the following information is general advice and to contact your specialist for any specific questions. The ARA recommends continuing taking your medications, including immunosuppressive treatments. They also confirm that Australian medications are sourced widely, and measures have been taken to ensure adequate provision for consumers needing the medications for approved conditions, including hydroxychloroquine (Plaquenil) and sulfasalazine (Salazopyrin). For more information please read the ARA statement located here
 Contacting us
We want our community to feel safe and informed during these difficult times. If you feel uncertain about any of the information you are receiving or would like to ask any questions, please do not hesitate to contact our staff members.
National Arthritis Infoline: 1800 011 041
Arthritis Australia email:
National Coronavirus Helpline: 1800 020 080
Copyright © 2020, Arthritis Australia, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.